Rescue of Infants With MCT8 Deficiency

NCT04143295 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-12-11

No results posted yet for this study

Summary

Monocarboxylate Transporter 8 (MCT8) deficiency (that is also known as Allan-Herndon-Dudley syndrome) is a rare X-linked inherited disorder of brain development that causes severe intellectual disability and problems with movement. This condition, which occurs almost exclusively in males, disrupts development from before birth.

Conditions

  • Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency

Interventions

DRUG

Diiodothyropropionic acid (DITPA)

Drug Administration

Sponsors & Collaborators

  • Roy E. Weiss, M.D.

    lead OTHER

Principal Investigators

  • Roy E Weiss, M.D. · University of Miami

Eligibility

Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04143295 on ClinicalTrials.gov